Bristol-Myers Squibb demonstrated notable trends in its growth portfolio moving into Q2 2025, even though its stock traded lower. BMY's Q2 2025 results exceeded revenue expectations, primarily due to continued strength in older drugs. However, its EPS didn't quite meet targets, triggering stock devaluation. Notably, the company received FDA endorsement for its TYK2 Inhibitor, Sotyktu. Furthermore, BMY partnered with Bain Capital, forming a new company specialising in developing immunology medications. Despite a few setbacks, Morgan Stanley maintains a Sell Rating on BMY. Meanwhile, Goldman Sachs keeps a Hold stance. BMY's Q2 2025 report revealed better-than-anticipated results due to strong performance from top-selling drugs. Interestingly, the company's Lupus study could potentially alter the game. BMY stock outperformed the broader market, sparking investor attention. A collaborative study between
Bristol-Myers Squibb and Pfizer could yield promising findings in Multiple Myeloma treatment. In spite of some stock market swings, BMY recorded robust growth and looks promising moving forward. General sentiment leans towards the company posing a potential long-term income source.
Bristol-Myers Squibb BMY News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 02 Aug 2025 12:37:34 GMT -
Rating 6
- Innovation 2
- Information 7
- Rumor -4
